Key Takeaway: ProKidney Corp. will participate in two significant healthcare conferences in November 2025. The Guggenheim Healthcare Innovation Conference will feature a fireside chat, while the Jefferies Global Healthcare Conference will include one-on-one meetings. These events aim to enhance investor engagement and showcase ProKidney's advancements in chronic kidney disease treatments.
Price reaction · baseline $3.04 (2025-10-28 close) · hit pre-market · clean, no other PROK news in the window
day 0 close · peak
+2%
Conference Participation Details
Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat
How to Access
Investors and the general public can listen to both sessions live at:
Archived versions will be available following the live events for a limited time.
Market Sentiment Analysis
POSITIVE FACTORS
ProKidney is actively engaging with the investment community.
Participation in major healthcare conferences highlights company visibility.
The company is advancing its innovative cellular therapy for CKD.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+32%
120-day peak, hindsight
Typical move
5.1%
average across 5 past catalysts
Cash runway
~15 mo
Low dilution risk
Lead asset
Renal Autologous Cell Therapy
Phase 3 · Type 2 Diabetes Mellitus
Full Press Release Details
WINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) --ProKidney Corp. (Nasdaq: PROK)(“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in November:
Guggenheim Healthcare Innovation Conference (Boston)Date:Wednesday, November 12, 2025Time:10:00am ETFormat:Fireside ChatWebcast:Link
Jefferies Global Healthcare Conference (London)Dates:November 17-20, 2025Format:1x1 Meetings
The live webcast of the fireside chat will be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website atwww.prokidney.com. Investors interested in one-on-one meetings should contact their banking representatives.
About ProKidney Corp.ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visitwww.prokidney.com.